BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30986472)

  • 1. High antitumor activity of Sortase A-generated anti-CD20 antibody fragment drug conjugates.
    Liu W; Zhao W; Bai X; Jin S; Li Y; Qiu C; Pan L; Ding D; Xu Y; Zhou Z; Chen S
    Eur J Pharm Sci; 2019 Jun; 134():81-92. PubMed ID: 30986472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
    Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
    Small; 2017 Feb; 13(6):. PubMed ID: 27873460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical studies of targeted therapies for CD20-positive B lymphoid malignancies by Ofatumumab conjugated with auristatin.
    Li ZH; Zhang Q; Wang HB; Zhang YN; Ding D; Pan LQ; Miao D; Xu S; Zhang C; Luo PH; Naranmandura H; Chen SQ
    Invest New Drugs; 2014 Feb; 32(1):75-86. PubMed ID: 23903896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A developed antibody-drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line.
    Abdollahpour-Alitappeh M; Hashemi Karouei SM; Lotfinia M; Amanzadeh A; Habibi-Anbouhi M
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1-8. PubMed ID: 29523024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.
    Gerber HP; Kung-Sutherland M; Stone I; Morris-Tilden C; Miyamoto J; McCormick R; Alley SC; Okeley N; Hayes B; Hernandez-Ilizaliturri FJ; McDonagh CF; Carter PJ; Benjamin D; Grewal IS
    Blood; 2009 Apr; 113(18):4352-61. PubMed ID: 19147785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
    Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
    J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
    Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
    Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytotoxic conjugate of highly internalizing tetravalent antibody for targeting FGFR1-overproducing cancer cells.
    Poźniak M; Porębska N; Krzyścik MA; Sokołowska-Wędzina A; Jastrzębski K; Sochacka M; Szymczyk J; Zakrzewska M; Otlewski J; Opaliński Ł
    Mol Med; 2021 May; 27(1):46. PubMed ID: 33962559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency.
    Beerli RR; Hell T; Merkel AS; Grawunder U
    PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific Conjugation of the Hinge Region for Homogeneous Preparation of Antibody Fragment-Drug Conjugate: A Case Study for Doxorubicin-PEG-anti-CD20 Fab' Synthesis.
    Zhou Z; Zhang J; Zhang Y; Ma G; Su Z
    Bioconjug Chem; 2016 Jan; 27(1):238-46. PubMed ID: 26700095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
    Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
    Front Immunol; 2018; 9():1799. PubMed ID: 30123222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An anti-HER2 antibody conjugated with monomethyl auristatin E is highly effective in HER2-positive human gastric cancer.
    Li H; Yu C; Jiang J; Huang C; Yao X; Xu Q; Yu F; Lou L; Fang J
    Cancer Biol Ther; 2016 Apr; 17(4):346-54. PubMed ID: 26853765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies.
    Hu XY; Wang R; Jin J; Liu XJ; Cui AL; Sun LQ; Li YP; Li Y; Wang YC; Zhen YS; Miao QF; Li ZR
    Mol Oncol; 2019 Feb; 13(2):246-263. PubMed ID: 30372581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Anti-GDNF Family Receptor Alpha 1 (GFRA1) Antibody-Drug Conjugate for the Treatment of Hormone Receptor-Positive Breast Cancer.
    Bhakta S; Crocker LM; Chen Y; Hazen M; Schutten MM; Li D; Kuijl C; Ohri R; Zhong F; Poon KA; Go MAT; Cheng E; Piskol R; Firestein R; Fourie-O'Donohue A; Kozak KR; Raab H; Hongo JA; Sampath D; Dennis MS; Scheller RH; Polakis P; Junutula JR
    Mol Cancer Ther; 2018 Mar; 17(3):638-649. PubMed ID: 29282299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response.
    Dela Cruz Chuh J; Go M; Chen Y; Guo J; Rafidi H; Mandikian D; Sun Y; Lin Z; Schneider K; Zhang P; Vij R; Sharpnack D; Chan P; de la Cruz C; Sadowsky J; Seshasayee D; Koerber JT; Pillow TH; Phillips GD; Rowntree RK; Boswell CA; Kozak KR; Polson AG; Polakis P; Yu SF; Dragovich PS; Agard NJ
    MAbs; 2021; 13(1):1862452. PubMed ID: 33382956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
    Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
    Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.